These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 2685578)

  • 1. [Kidney involvement in autoimmune diseases].
    Mehls O; Müller-Wiefel DE; Wingen AM
    Monatsschr Kinderheilkd; 1989 Oct; 137(10):638-42. PubMed ID: 2685578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Simultaneous presence of antibodies against the glomerular basement membrane and anti-myeloperoxidase antibodies in 2 patients with rapidly progressive glomerulonephritis].
    Díaz Rodríguez C; Costero O; Torre A; De Alvaro F; Gil F; Picazo ML; Martínez-Ara J
    Nefrologia; 2002; 22(2):190-5. PubMed ID: 12085420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [What is the role of autoimmune processes in nephropathies?].
    Ehrich JH; Oemar BS; Bruijn JA
    Monatsschr Kinderheilkd; 1990 Nov; 138(11):724-9. PubMed ID: 2290431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New advances in understanding the treatment of glomerulonephritis.
    Lockwood CM
    Clin Nephrol; 1986; 26 Suppl 1():S76-80. PubMed ID: 3829472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmunity and glomerulonephritis.
    Lockwood CM; Bowman C; Bakes D; Pressey A; Dash A
    Adv Nephrol Necker Hosp; 1987; 16():291-306. PubMed ID: 3101428
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rapid-detection GBM-ANCA ELISA. An emergency tool for the early diagnosis of type I and II rapidly progressive glomerulonephritis].
    Arranz O; Ara J; Rodríguez R; Poveda R; Serra A; Solé-Amigó J; Fort J; Mirapeix E; Darnell A
    Nefrologia; 2001; 21(4):349-54. PubMed ID: 11816510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ANCA-associated vasculitis].
    Sinico RA; Sabadini E; Boeri R; Radice A
    G Ital Nefrol; 2002; 19(2):125-36. PubMed ID: 12195410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis.
    Rutgers A; Slot M; van Paassen P; van Breda Vriesman P; Heeringa P; Tervaert JW
    Am J Kidney Dis; 2005 Aug; 46(2):253-62. PubMed ID: 16112043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glomerular chemokine expression and the effect of steroid and cyclophosphamide pulse therapy in human crescentic glomerulonephritis.
    Chen S; Liu Z; Chen H; Zhou H; Wang J; Li L
    Chin Med J (Engl); 2002 Sep; 115(9):1301-7. PubMed ID: 12411099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunosuppressive therapy of glomerulonephritis--controlled studies].
    Ferrari P; Frey FJ
    Ther Umsch; 1993 Feb; 50(2):119-29. PubMed ID: 8456416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pauci-immune crescentic glomerulonephritis.
    Gupta RK
    Indian J Pathol Microbiol; 2003 Jul; 46(3):357-66. PubMed ID: 15025274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of cellular immunity in the pathogenesis of glomerulonephritis].
    Kacprzyk F; Orłowski Z
    Postepy Hig Med Dosw; 1989; 43(2-4):199-212. PubMed ID: 2702352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Crescentic glomerulonephritis].
    Esnault VL; Moreau A; Testa A; Besnier D
    Nephrol Ther; 2006 Dec; 2(7):446-60. PubMed ID: 17185236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autoantibodies in nephrology].
    Weber M; Marx M
    Internist (Berl); 1995 Mar; 36(3):270-6. PubMed ID: 7737820
    [No Abstract]   [Full Text] [Related]  

  • 15. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
    Danieli MG; Palmieri C; Salvi A; Refe MC; Strusi AS; Danieli G
    J Clin Apher; 2002; 17(2):72-7. PubMed ID: 12210709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auto-antibodies of the IgD class.
    Kantor GL; Van Herle AJ; Barnett EV
    Clin Exp Immunol; 1970 Jun; 6(6):951-62. PubMed ID: 4920553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The course and prognosis of mesangioproliferative glomerulonephritis].
    Shilov EM; Tareeva IE; Ivanov AA; Troepol'skaia OV; Krasnova TN; Varshavskiĭ VA; Proskurneva EP; Ivanova LV; Khudova IIu; Miroshnichenko NG
    Ter Arkh; 2002; 74(6):11-8. PubMed ID: 12136475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection.
    Wilson LE; Widman D; Dikman SH; Gorevic PD
    Semin Arthritis Rheum; 2002 Dec; 32(3):163-73. PubMed ID: 12528081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.